Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2069041

Liver Cancer Partnering 2009-2014

Description:
The Liver Cancer Partnering 2009-2014 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 25links to online copies of actual liver cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of liver cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in liver cancer partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading liver cancer deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of liver cancer partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of liver cancer technologies and products.

Report scope

Liver Cancer Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to liver cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in liver cancer dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
Access to over 25 liver cancer contract documents
The leading lymphoma deals by value since 2009
In Liver Cancer Partnering 2009-2014, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
Contents:
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in liver cancer partnering

2.1. Introduction
2.2. Liver cancer partnering over the years
2.3. Bigpharma liver cancer dealmaking activity
2.4. Liver cancer partnering by deal type
2.5. Liver cancer partnering industry sector
2.6. Liver cancer partnering by stage of development
2.7. Liver cancer partnering by technology type
2.8. Disclosed financial deal terms for liver cancer partnering
2.8.1 Liver cancer headline values
2.8.2 Liver cancer upfront payments
2.8.3 Liver cancer milestone payments
2.8.4 Liver cancer royalty rates
Chapter 3 – Leading liver cancer deals

3.1. Introduction
3.2. Top liver cancer deals by value
3.3. Top liver cancer deals involving bigpharma
Chapter 4 – Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
Chapter 5 – Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices

Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures

Figure 1: Liver cancer partnering since 2009
Figure 2: Bigpharma – top 50 – liver cancer deals 2009 to 2011
Figure 3: Bigpharma liver cancer deal frequency – 2009 to 2011
Figure 4: Liver cancer partnering by deal type since 2009
Figure 5: Liver cancer partnering by industry sector since 2009
Figure 6: Liver cancer partnering by stage of development since 2009
Figure 7: Liver cancer partnering by technology type since 2009
Figure 8: Liver cancer deals with a headline value
Figure 9: Liver cancer deals with upfront payment values
Figure 10: Liver cancer deals with milestone payments
Figure 11: Liver cancer deals with royalty rates, %
Figure 12: Top liver cancer deals by value since 2009
Figure 13: Top liver cancer deals signed by bigpharma value since 2009
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
 
Companies Mentioned
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2069041

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Aug 27th 2014
8:15:56 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Liver Cancer Partnering 2009-2014

Web Address

http://www.researchandmarkets.com/reports/2069041

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
CD ROM USD 1,195 + USD 67 Shipping/Handling *
Hard Copy and CD ROM USD 3,995 + USD 67 Shipping/Handling *
Electronic (PDF) - Single User USD 695
Electronic (PDF) - 1 - 5 Users USD 1,095
Electronic (PDF) - Enterprisewide USD 3,495

* Shipping/Handling is only charged once per order.

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Aug 27th 2014
8:15:56 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)